Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.42 |
| ▸ | NAMPT | P43490 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19725938 | 0.94 | NAMPT (0.43) | GPR119NAMPTCYP3A4CYP2C9HTR6 | |
| SCHEMBL17951163 | 0.84 | GPR119 (0.43) | GPR119CYP3A4CYP2C9HTR6BCHE | |
| SCHEMBL10227674 | 0.83 | GPR119 (0.49) | GPR119NAMPTCYP3A4CYP2C9HTR6 | |
| SCHEMBL10228635 | 0.82 | GPR119 (0.55) | GPR119CYP3A4CYP2C9HTR6BCHE | |
| SCHEMBL6128795 | 0.82 | GPR119 (0.55) | GPR119CYP3A4CYP2C9HTR6BCHE | |
| SCHEMBL17583115 | 0.82 | GPR119 (0.60) | GPR119CYP3A4CYP2C9HTR6MMP13 | |
| SCHEMBL17951145 | 0.82 | MAP4K4 (0.41) | GPR119NAMPTHTR6BCHE | |
| SCHEMBL6128886 | 0.81 | GPR119 (0.49) | GPR119CYP3A4CYP2C9HTR6BCHE | |
| SCHEMBL2728373 | 0.81 | GPR119 (0.49) | GPR119CYP3A4CYP2C9HTR6BCHE | |
| SCHEMBL17545832 | 0.81 | GPR119 (0.49) | GPR119CYP3A4CYP2C9HTR6BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360794-A1 | JAK INHIBITOR | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2017-12-21 | — | — | US | disclosed |
| US-20170360794-A1 | JAK INHIBITOR | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360794-A1 | JAK INHIBITOR | JAK2, JAK1, JAK3 | GPR119 1493/4885NAMPT 1808/4885CYP3A4 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.